Control and Elimination of Hepatitis C Virus Among People With HIV in Australia
Author Information
Author(s): Marianne Martinello, Joanne Carson, Jeffrey Post, Robert Finlayson, David Baker, Phillip Read, David Shaw, Mark Bloch, Joseph Doyle, Margaret Hellard, Ecaterina Filep, Samira Hosseini-Hooshyar, Gregory Dore, Gail V. Matthews
Primary Institution: The Kirby Institute, University of New South Wales, Sydney, Australia
Hypothesis
HCV elimination would be feasible in this population, given the relative population size, high proportion diagnosed and linked to care, availability of harm reduction for people who inject drugs, and broad DAA access.
Conclusion
Universal access and rapid DAA uptake were associated with a dramatic reduction in HCV prevalence and reinfection incidence among people with HIV in Australia to levels consistent with microelimination.
Supporting Evidence
- DAA treatment uptake increased from 12% in 2014 to 92% in 2022.
- HCV RNA prevalence declined from 85% at enrollment to 0.5% at follow-up 2.
- Reinfection incidence was 1.41 per 100 person-years.
- 30 deaths occurred during the study, with stable mortality incidence.
Takeaway
This study shows that giving everyone access to hepatitis C treatment helped a lot of people with HIV in Australia get better and reduced the number of new infections.
Methodology
The CEASE cohort study enrolled adults with HIV with past or current HCV infection from 14 clinics, collecting data at enrollment and two follow-ups over several years.
Potential Biases
The cohort may have been biased toward those more likely to initiate treatment.
Limitations
The findings may not be generalizable to the broader population with HIV due to the specific demographics of the CEASE cohort.
Participant Demographics
95% male, 83% gay or bisexual men, median age 49 years.
Statistical Information
Confidence Interval
95% CI, 81%–88%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website